01 · THE CUSTOMER PROBLEM
Gene-therapy programs need carriers that protect nucleic acids, control particle properties and support uptake without relying exclusively on viral vectors.
Mykito tunes purity, MW, DDA, charge ratio and particle architecture together, giving formulation teams a controlled starting point for DNA and RNA carrier screening.
Chitosan’s cationic charge enables it to complex negatively charged nucleic acids without relying on a viral vector.
02 · RECOMMENDED STARTING POINT
Start with the material designed for the decision.
Molecular weight, degree of deacetylation, charge ratio and particle architecture can be tuned together to develop non-viral DNA and siRNA delivery systems with stronger stability and transfection performance.
Without the shell
Controlled fungal sourcing supports a traceable, non-animal supply strategy.
Specification engineered
MW, DDA, purity, charge density and format are selected around the target result.
Application ready
Powder is only the starting point; Mykito also develops films, fibers, gels, coatings and formulations.
One technical partner
Material selection, formulation support and the validation plan are connected from the first sample.
03 · PERFORMANCE TARGETS
Build toward outcomes a buyer can measure.
Non-viral delivery
Cationic chitosan can condense DNA or RNA into polyplexes and nanoparticles for non-viral vector research.
In vivo siRNA development
Protected siRNA complexes can be engineered for stability, biodistribution and gene-silencing studies in vivo.
Transfection optimization
MW, DDA, N/P ratio, particle size and functionalization can be screened to improve uptake and transfection efficiency.
Targeted constructs
Reactive groups support ligand conjugation and tissue- or cell-targeting development.
04 · GO / NO-GO CRITERIA
Define the evidence before testing begins.
The first program is designed around three decision-making outputs—not an open-ended material trial.
Cargo binding and protection
Particle size, PDI and stability
Cytocompatibility, uptake and transfection
05 · FROM SAMPLE TO DECISION
A practical application program,
not a bag of powder.
Define
Agree on the function, baseline, constraints and measurable success criteria.
Screen
Select the MW, DDA, purity, dose and physical format that fit the application.
Validate
Test the winning system in the finished formulation, device, process or use environment.
Recommended first request: A small EndoFree MW/DDA screening set for nucleic-acid complexation studies.
Start the Sample Brief06 · WHY CHITOSAN
Cationic complexation + matrix control
Protonated amino groups can interact with selected anionic actives, polymers and biological surfaces. MW, DDA, crosslinking and architecture then provide levers for adhesion, protection and release.
There is no universal concentration. Grade and dose are screened against pH, interacting ingredients, process conditions and the target performance profile.
Route-specific purity, residuals, compatibility, stability and regulatory suitability are established for the finished system.